Physician profile
Natalie Elizabeth George
NPI 1114298510
$539,946.65
in general payments reported to CMS, 2019-2025
30 companies · $126K in 2025
The $126K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34K · 2022: $110K · 2023: $133K · 2024: $137K · 2025: $126K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $307K · Travel and Lodging: $28K · Food and Beverage: $21K · Consulting Fee: $21K · Honoraria: $19K · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $306,837.75 |
| Travel and Lodging | $28,277.89 |
| Food and Beverage | $20,858.50 |
| Consulting Fee | $20,629.94 |
| Honoraria | $18,900.00 |
| Education | $252.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $196,512.64 | 2021-2025 | |
| Lilly USA, LLC | $63,579.18 | 2021-2025 | Ebglyss, Taltz |
| Janssen Biotech, INC. | $61,675.91 | 2021-2025 | Tremfya |
| Dermavant Sciences, INC. | $48,044.81 | 2022-2024 | Vtama |
| Organon LLC | $29,285.09 | 2025 | Vtama, Nexplanon |
| Regeneron Healthcare Solutions, INC. | $27,876.05 | 2021-2025 | Dupixent |
| Incyte Corporation | $26,786.38 | 2021-2025 | Opzelura, Opzelura |
| Genzyme Corporation | $25,265.93 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $24,404.31 | 2021-2025 | Sotyktu |
| Janssen Scientific Affairs, LLC | $14,282.00 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $6,954.30 | 2021-2025 | Cosentyx |
| Ucb, INC. | $5,773.10 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $4,571.68 | 2021-2025 | Adbry, Anzupgo |
| Epi Health, LLC | $1,685.17 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $961.67 | 2021-2025 | Siliq, Targretin, Duobrii |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $600.69 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $331.84 | 2021-2025 | Ilumya |
| Arcutis Biotherapeutics, INC. | $330.21 | 2024-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $299.20 | 2021 | |
| Galderma Laboratories, L.P. | $202.39 | 2024-2025 | Nemluvio, Aklief |
| Amgen INC. | $108.80 | 2021-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Organogenesis INC. | $88.23 | 2023 | Puraply |
| Journey Medical Corporation | $62.86 | 2023-2025 | |
| Botanix Sb INC | $57.07 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $33.91 | 2023-2025 | |
| Celgene Corporation | $26.00 | 2022 | |
| Paratek Pharmaceuticals, INC. | $19.47 | 2025 | Nuzyra |
| Tactile Systems Technology INC | $14.51 | 2023 | Entre Plus, Flexitouch Plus |
| Fresenius Kabi USA, LLC | $13.26 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.